JP7111630B2 - 炎症性腸疾患用のバイオマーカー - Google Patents

炎症性腸疾患用のバイオマーカー Download PDF

Info

Publication number
JP7111630B2
JP7111630B2 JP2018565368A JP2018565368A JP7111630B2 JP 7111630 B2 JP7111630 B2 JP 7111630B2 JP 2018565368 A JP2018565368 A JP 2018565368A JP 2018565368 A JP2018565368 A JP 2018565368A JP 7111630 B2 JP7111630 B2 JP 7111630B2
Authority
JP
Japan
Prior art keywords
ibd
genes
expression
risk
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018565368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527039A (ja
JP2019527039A5 (enExample
Inventor
リオンズ，ポール，エー．
マッキニー，オーエン，エフ．
ビアシ，ダニエル
リー，ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2019527039A publication Critical patent/JP2019527039A/ja
Publication of JP2019527039A5 publication Critical patent/JP2019527039A5/ja
Application granted granted Critical
Publication of JP7111630B2 publication Critical patent/JP7111630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2018565368A 2016-07-05 2017-07-05 炎症性腸疾患用のバイオマーカー Active JP7111630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1611738.4A GB201611738D0 (en) 2016-07-05 2016-07-05 Biomarkers for inflammatory bowel disease
GB1611738.4 2016-07-05
PCT/IB2017/000997 WO2018007872A1 (en) 2016-07-05 2017-07-05 Biomarkers for inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020136564A Division JP2020198884A (ja) 2016-07-05 2020-08-13 炎症性腸疾患用のバイオマーカー

Publications (3)

Publication Number Publication Date
JP2019527039A JP2019527039A (ja) 2019-09-26
JP2019527039A5 JP2019527039A5 (enExample) 2019-11-28
JP7111630B2 true JP7111630B2 (ja) 2022-08-02

Family

ID=56891052

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018565368A Active JP7111630B2 (ja) 2016-07-05 2017-07-05 炎症性腸疾患用のバイオマーカー
JP2020136564A Pending JP2020198884A (ja) 2016-07-05 2020-08-13 炎症性腸疾患用のバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020136564A Pending JP2020198884A (ja) 2016-07-05 2020-08-13 炎症性腸疾患用のバイオマーカー

Country Status (15)

Country Link
US (3) US11041206B2 (enExample)
EP (1) EP3481964B1 (enExample)
JP (2) JP7111630B2 (enExample)
KR (1) KR102352847B1 (enExample)
CN (1) CN109477145B (enExample)
AU (1) AU2017293417B2 (enExample)
CA (1) CA3029912A1 (enExample)
DK (1) DK3481964T3 (enExample)
ES (1) ES2906192T3 (enExample)
GB (1) GB201611738D0 (enExample)
HU (1) HUE058197T2 (enExample)
LT (1) LT3481964T (enExample)
PL (1) PL3481964T3 (enExample)
PT (1) PT3481964T (enExample)
WO (1) WO2018007872A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10515408B2 (en) 2003-08-13 2019-12-24 Bgc Partners, Inc. Systems and methods for bid/offer liquidity spread trading
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease
CA3047302C (en) * 2016-12-14 2024-01-02 Tracy WARREN System and methods for developing and using a microbiome-based action component for patient health
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3866920B1 (en) 2018-10-18 2025-12-10 T.J.Smith And Nephew, Limited Tissue treatment device
GB201817052D0 (en) 2018-10-19 2018-12-05 Smith & Nephew Tissue treatment device
CN110400603A (zh) * 2019-07-23 2019-11-01 中国石油大学(华东) 基于格局加权的ibd矩阵计算方法
GB201912518D0 (en) 2019-08-30 2019-10-16 Cambridge Entpr Ltd Inflammatory disease prognostics
GB202005867D0 (en) 2020-04-22 2020-06-03 Smith & Nephew Tissue treatment device
GB202100527D0 (en) 2021-01-15 2021-03-03 Smith & Nephew Systems and methods for managing operation of wound dressings or wound treatment devices
WO2022190036A2 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Methods for predicting treatment response in ulcerative colitis
CN114517228A (zh) * 2021-12-31 2022-05-20 青岛锐翌精准医学检验有限公司 炎症性肠病标志基因及其应用
CN114645088B (zh) * 2022-04-22 2023-12-15 广东省人民医院 克罗恩病进展风险相关评估基因集、试剂盒、应用和系统
EP4606910A1 (en) * 2024-02-21 2025-08-27 Royal College of Surgeons in Ireland Diagnostic and prognostic methods relating to ulcerative colitis

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501332A (ja) 2004-06-02 2008-01-24 ダイアゲニック エイエス 癌診断のためのオリゴヌクレオチド
JP2008545437A (ja) 2005-06-06 2008-12-18 ワイス 炎症性腸疾患についての末梢血単核細胞の発現プロフィール
JP2011509071A (ja) 2007-11-29 2011-03-24 ジェネンテック， インコーポレイテッド 炎症性腸疾患のための遺伝子発現マーカー
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
JP2015505300A (ja) 2011-11-23 2015-02-19 アムジエン・インコーポレーテツド インターフェロンγに対する抗体を使用した治療方法
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
JP2015532425A (ja) 2012-10-05 2015-11-09 ネステク ソシエテ アノニム 粘膜治癒を予測及びモニタリングするための方法
WO2016066288A1 (en) 2014-10-28 2016-05-06 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for inflammatory bowel disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610949D0 (en) * 2006-06-02 2006-07-12 Glaxosmithkline Biolog Sa Method
US20100222262A1 (en) * 2008-04-02 2010-09-02 Metaproteomics, Llc Substituted 1, 3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
US20120003228A1 (en) * 2009-01-20 2012-01-05 Cambridge Enterprise Limited Methods for predicting autoimmune disease risk
EP2419532A1 (en) * 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
EP2272977A1 (en) 2009-07-08 2011-01-12 Universite Libre De Bruxelles Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome
WO2013138497A1 (en) 2012-03-13 2013-09-19 Baylor Research Institute Early detection of tuberculosis treatment response
EP2931923A1 (en) 2012-12-13 2015-10-21 Baylor Research Institute Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
CN105683392A (zh) * 2013-03-15 2016-06-15 博德研究所 树突细胞应答基因表达、物质组合物及其使用方法
US10619210B2 (en) * 2014-02-07 2020-04-14 The Johns Hopkins University Predicting response to epigenetic drug therapy
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3262193A2 (en) * 2015-02-26 2018-01-03 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
JP2018512876A (ja) 2015-04-22 2018-05-24 ミナ セラピューティクス リミテッド ｓａＲＮＡ組成物および使用方法
US20170003277A1 (en) * 2015-07-01 2017-01-05 Michael Hayden Biological characterization of a glatiramer acetate related drug product using mammalian and human cells
GB201611738D0 (en) 2016-07-05 2016-08-17 Cambridge Entpr Ltd Biomarkers for inflammatory bowel disease

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501332A (ja) 2004-06-02 2008-01-24 ダイアゲニック エイエス 癌診断のためのオリゴヌクレオチド
JP2008545437A (ja) 2005-06-06 2008-12-18 ワイス 炎症性腸疾患についての末梢血単核細胞の発現プロフィール
JP2011509071A (ja) 2007-11-29 2011-03-24 ジェネンテック， インコーポレイテッド 炎症性腸疾患のための遺伝子発現マーカー
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
JP2015505300A (ja) 2011-11-23 2015-02-19 アムジエン・インコーポレーテツド インターフェロンγに対する抗体を使用した治療方法
JP2015532425A (ja) 2012-10-05 2015-11-09 ネステク ソシエテ アノニム 粘膜治癒を予測及びモニタリングするための方法
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2016066288A1 (en) 2014-10-28 2016-05-06 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for inflammatory bowel disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｎａｔ．Ｍｅｄ．（２０１０）Ｖｏｌ．１６，Ｎｏ．５，ｐ．５８６－５９１

Also Published As

Publication number Publication date
CN109477145A (zh) 2019-03-15
JP2019527039A (ja) 2019-09-26
GB201611738D0 (en) 2016-08-17
US20180010187A1 (en) 2018-01-11
AU2017293417A1 (en) 2019-02-21
US10202651B2 (en) 2019-02-12
US10640829B2 (en) 2020-05-05
NZ750396A (en) 2020-12-18
US20180010189A1 (en) 2018-01-11
PL3481964T3 (pl) 2022-04-11
JP2020198884A (ja) 2020-12-17
PT3481964T (pt) 2022-02-17
EP3481964B1 (en) 2021-12-29
WO2018007872A9 (en) 2018-03-15
US20190032140A1 (en) 2019-01-31
WO2018007872A1 (en) 2018-01-11
CA3029912A1 (en) 2018-01-11
DK3481964T3 (da) 2022-02-07
HUE058197T2 (hu) 2022-07-28
AU2017293417B2 (en) 2019-11-14
KR102352847B1 (ko) 2022-01-17
CN109477145B (zh) 2021-04-09
EP3481964A1 (en) 2019-05-15
US11041206B2 (en) 2021-06-22
LT3481964T (lt) 2022-04-11
ES2906192T3 (es) 2022-04-13
KR20190025637A (ko) 2019-03-11

Similar Documents

Publication Publication Date Title
JP7111630B2 (ja) 炎症性腸疾患用のバイオマーカー
Li et al. A peripheral blood diagnostic test for acute rejection in renal transplantation
US10260097B2 (en) Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
US11091809B2 (en) Molecular diagnostic test for cancer
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
EP3430172A1 (en) Methods of diagnosing inflammatory bowel disease through rnaset2
Hu et al. Association between the SIRT1 mRNA expression and acute coronary syndrome
US10793911B2 (en) Host DNA as a biomarker of Crohn's disease
US20240247315A1 (en) Diagnosing inflammatory bowel diseases
WO2015179777A2 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
KR102849864B1 (ko) 가와사키병을 갖는 대상체를 확인하는 방법
HK40007518B (en) Biomarkers for inflammatory bowel disease
NZ750396B2 (en) Biomarkers for inflammatory bowel disease
HK40003433B (en) Biomarkers for inflammatory bowel disease
HK40003433A (en) Biomarkers for inflammatory bowel disease
WO2024168038A2 (en) Method for identifying kidney allograft rejection genes in urine and utility of making those measurements

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191015

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191015

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200703

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200721

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200821

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200824

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201023

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201027

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210416

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220118

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220302

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220525

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220602

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220627

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220721

R150 Certificate of patent or registration of utility model

Ref document number: 7111630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150